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SPECIAL ARTICLE | Hepatology CommuniCations, Vol. 3, no. 2, 2019  
Extracellular Vesicles in Liver Diseases: 
Meeting Report from the International 
Liver Congress 2018
Jesus M. Banales,1 Ariel E. Feldstein,2 Hanna Sänger,3 Veronika Lukacs-Kornek,4 Gyongyi Szabo,5 and Miroslaw Kornek6,7
Extracellular vesicles (EVs) are small and heterogeneous membrane-bound structures released by cells and found in 
all biological f luids. They are effective intercellular communicators, acting on a number of close and/or distant target 
cells. EV cargo may ref lect the cell of origin as well as the specific stress that induces their formation and release. 
They transport a variety of bioactive molecules, including messenger RNA, noncoding RNAs, proteins, lipids, and 
metabolites, that can be transferred among cells, regulating various cell responses. Alteration in the concentration 
and composition of EVs in biological f luids is a typical hallmark of pathologies in different liver diseases. Circulating 
EVs can serve as biomarkers or as messengers following uptake by other cells. This review is a meeting report from 
the International Liver Congress 2018 (European Association for the Study of the Liver) celebrated in Paris 
(Symposium: Extracellular vesicles and signal transmission) that discusses the role of EVs in several liver diseases, 
highlighting their potential value as disease biomarkers and therapeutic opportunities. ( Hepatology Communications  
2019;3:305-315).
Extracellular vesicles (EVs) are small cell- derived structures enveloped by a double-layer membrane that are shed by cells as a mecha-
nism of horizontal communication. First described as 
an outgrowth of platelet activity or sample contamina-
tion, the role of EVs remained largely unexplored(1,2) 
until the early 2000s when growing enthusiasm for 
the field of EV biology and pathobiology resulted in 
increasing numbers of new publications each year. 
The potential of EVs as diagnostic and prognostic 
tools is being increasingly recognized by the scien-
tific community and awaits translation into human 
medicine.
Currently, three major types of EVs are recog-
nized: exosomes, microvesicles (MVs), and apoptotic 
bodies. Despite some disagreements over their exact 
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definitions, essentially these three types of EVs dif-
fer in size and mode of production. Exosomes, which 
are up to 150 to 200 nm in diameter, represent the 
smallest type.(3) They are produced within the endo-
somal membrane system of their parental cells and 
are transported toward the plasma membrane inside 
endosomal vesicles, also known as multivesicular 
bodies (MVBs).(3) These MVBs merge with the cell 
plasma membrane and shed exosomes into the extra-
cellular space by exocytosis.(4) In contrast, MVs, also 
referred to as microparticles (MPs) or ectosomes, are 
released through a coordinated budding process of the 
cell plasma membrane, resulting in their membrane 
composition mirroring that of the parental cells.(5,6) 
Characterization of MVs can be used to identify the 
cell type that was activated to release a particular 
population of MVs.(7) MVs range from 0.1 to 1 µm 
in diameter and are characterized by a bilayer mem-
brane containing externalized phosphatidylserine.(8,9) 
In cells undergoing regulated death, apoptotic signals 
induce their fragmentation into apoptotic bodies,(10) 
which represent the largest EVs and range from 1 to 
5 µm in diameter.(11)
It is believed that all cell types of the human body 
are capable of releasing EVs either constitutively or 
as adaptive cellular responses.(8) Based on their abil-
ity to travel through biological fluids, EVs function 
as messengers, communicating between distant sites 
while maintaining a high specificity (SPE) to their 
destination.(12-14) Their cargo can comprise various 
types of molecules, making them ideal regulators 
of biological processes. EVs can transport short 
and long nucleic acids (microRNAs [miRs/miR-
NAs], small interfering RNAs, messenger RNAs, 
or long noncoding RNAs [lncRNAs]), proteins 
(cytosolic, cytoskeletal, membrane-bound transport-
ers and receptors, enzymes, adhesion molecules), 
lipids (sphingomyelin, phosphatidylserine, choles-
terol, ceramide), and metabolites.(15) Recently, their 
potential as vehicles for effective and site-specific 
drug delivery has been implemented.(16) By fusing 
with a recipient cell, EVs integrate their membrane 
into the phospholipid bilayer of the receiving cell, 
thereby transferring their content into the recipient 
and modulating intracellular pathways.(5) EVs can 
also be taken up by recipient cells through protein 
and/or lipid interactions, further leading to their 
endocytosis.(13)
In earlier years research focused on detection and 
quantification of EVs; however, since the mid-2000s 
the analysis of their composition and the study of 
their biological functions have become the center of 
attention. As EV composition and content reflect fea-
tures of the parental cells, EVs represent invaluable 
indicators of mechanisms driving pathobiological pro-
cesses.(5,6) By isolating circulating exosomes or MVs 
from patient blood, it is possible to create disease-spe-
cific EV profiles with respect to their surface antigens 
and/or whole RNA, protein, and lipidomic content. 
Apart from peripheral blood, various other body flu-
ids have been used for EV characterization, includ-
ing saliva,(17) urine,(18) breast milk,(19) cerebrospinal 
fluid,(20) and bile.(21) Accordingly, numerous liver con-
ditions have been evaluated in terms of their EV pro-
file and pathobiological relevance, including, among 
others, nonalcoholic fatty liver disease (NAFLD), 
nonalcoholic steatohepatitis (NASH), alcoholic hepa-
titis (AH), cirrhosis, hepatocellular carcinoma (HCC), 
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cholangiocarcinoma (CCA), and other cholangiopa-
thies (such as primary sclerosing cholangitis [PSC]). 
In the liver, hepatocytes, immune cells, endothelial 
cells, hepatic stellate cells (HSCs), and cholangiocytes 
all contribute to EV production.(22-25)
NAFLD and NASH
Lipotoxicity, a process by which accumulation of 
certain toxic lipids (e.g., saturated free fatty acids) 
in hepatocytes triggers various molecular pathways 
of cell stress and eventually results in cell death, 
has evolved as a key event along NAFLD progres-
sion to NASH and eventually to HCC.(4) During 
the process of lipotoxicity, hepatocytes release large 
numbers of EVs that may act on different target 
cells and contribute to key processes involved in 
NAFLD pathogenesis, including immune modu-
lation, angiogenesis, and fibrosis (Fig. 1). The EVs 
produced and released during NAFLD progression 
have specific antigenic composition, reflecting the 
pathologic alterations typical of its progression, and 
present miRs and proteins abundantly found in the 
liver. Additionally, the EV levels are dynamic and 
change over time, correlating with changes in liver 
histopathology.
Proteome analysis of circulating EVs from mouse 
models of NAFLD demonstrated that these ves-
icles carry a selective antigenic composition.(26) 
Hierarchical clustering analysis allowed for discrim-
ination of mice with established NASH from those 
with isolated steatosis and normal livers, identifying 
a proteomic signature in serum EVs that might be 
used to noninvasively diagnose NASH. Notably, the 
level of circulating EVs released during diet-induced 
mouse models of NAFLD strongly correlated with 
histopathologic features of NAFLD (i.e., fat content, 
fibrosis, cell death, and pathologic angiogenesis) and 
were enriched in miR-122 and miR-192, two miRs 
highly expressed in hepatocytes. The level of these 
miRNAs increased in EVs and decreased in livers 
over time during NAFLD progression. The release 
of these miRs from stressed or damaged hepatocytes 
in EVs during NAFLD progression may provide an 
attractive explanation for the decreased expression 
Fig. 1. Extracellular vesicles in the pathogenesis of fatty liver disease. During the process of lipotoxicity, hepatocytes release a large 
amount of EVs that may then act on various target cells in the local environment, contributing to key processes involved in NAFLD 
pathogenesis, including immune modulation, angiogenesis, and fibrosis. Additionally, EVs may be released to the systemic circulation 
and can be potentially used to noninvasively monitor the extent of liver injury. Abbreviation: qHSC, quiescent HSC. 
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level of miR-122 found in the livers of patients 
with NASH.(27) In contrast to healthy individuals 
where miR-122 is present in circulation only in the 
Argonaut 2 (Ago2) complex fraction, the majority 
of serum miR-122 circulates in Ago2-free forms in 
patients with NAFLD,(28) although its specific com-
partment is still unknown.
Patients with NASH might also present changes 
in the immune-derived EV composition because 
increased circulating levels of leukoendothelial-de-
rived clusters of differentiation (CD)31+/41−, pan-leu-
kocyte-derived CD11a+, lymphocyte-derived CD4+, 
and erythrocyte-derived CD235a+ EVs occur in 
patients with liver cirrhosis.(29,30) Additionally, MVs 
positive for inflammatory cell markers, such as CD4+ 
cells, CD8+ T cells, or CD14+ monocytes/invariant 
natural killer cells, are detected in plasma of patients 
with various liver conditions.(7) However, EVs derived 
from inflammatory cells are not specific and may be 
elevated in a number of immune and inflammatory 
conditions associated with their activation, thus limit-
ing their utility as biomarkers of liver disease.
At the pathobiological level, it has been shown 
that MPs from plasma of both mice and patients 
with NASH contain high levels of mitochondrial 
DNA and intact mitochondria that are able to trig-
ger toll-like receptor 9 signaling, which is critical 
for NASH development.(31) Moreover, serum EVs 
originated from the liver of mice with diet-induced 
NASH triggered migration and tubular structure for-
mation when applied to endothelial cells in vitro.(32) 
The angiogenic effects of hepatocyte-derived MVs 
underexposed to saturated fatty acids involved a 
vanin-1 (VNN1)-dependent uptake of EVs by endo-
thelial cells (i.e., an enzyme located on the surface of 
the vesicles). Similarly, EVs released by hepatocytes 
exposed to lipotoxicity are efficiently internalized into 
HSCs through a VNN1-dependent mechanism.(33) 
The internalization of vesicles induced a phenotypic 
switch of HSCs from quiescent to activated colla-
gen-producing myofibroblasts.(33) These data suggest 
that pathologic angiogenesis and fibrosis could be 
reduced by preventing endothelial cells and HSCs 
from internalizing VNN1-positive EVs from lipo-
toxic hepatocytes.
On the other hand, miR-128-3p was found 
enriched in EVs derived from fat-laden hepatocytes 
in the liver of two murine diet-induced NAFLD/
NASH models(33) and in the liver of patients with 
NASH.(27) This miR is selectively transferred through 
hepatocyte-derived EVs into HSCs, promoting HSC 
activation through direct targeting of peroxisome 
proliferator-activated receptor gamma (PPAR-γ) 
expression. PPAR-γ is a member of the nuclear hor-
mone-receptor superfamily that modulates HSC qui-
escence. PPAR-γ expression progressively decreases 
along HSC activation and is completely depleted in 
fully activated HSCs,(34) highlighting the important 
role of the EV transfer of miRs in the pathogenesis of 
NAFLD/NASH.
Regarding the mechanisms of EV biogenesis in 
NASH, mixed lineage kinase 3 was shown to mediate 
the release of chemokine (C-X-C motif ) ligand 10 in 
exosomes from lipotoxic hepatocytes, and these exo-
somes induced macrophage chemotaxis in NASH.(35) 
Lipid-induced signaling can also cause the release of 
EVs with inflammatory potential into hepatocytes,(36) 
while the ceramide transport protein steroidogenic 
acute regulatory protein-related lipid transfer domain 
11 has been recently uncovered as a novel modula-
tor of exosome biogenesis during lipotoxic insult to 
hepatocytes.(37)
Alcoholic Liver Disease and 
Alcoholic Hepatitis
AH, the clinically severe manifestation of alcoholic 
liver disease (ALD), represents one of the most com-
mon etiologies of progressive liver diseases leading to 
cirrhosis and predisposing to HCC. EVs have been 
explored as biomarkers for ALD and AH. Moreover, 
their biodistribution, cellular sources, biological 
effects, and therapeutic potential have been investi-
gated (Fig. 2).
The numbers of circulating EVs were found to 
be increased in mouse models of ALD as well as in 
patients with AH.(22) The majority of these EVs are 
exosomes (40 and 200 nm) and some MVs (200 and 
1,000 nm). Screening of the EV cargo revealed spe-
cific changes in miR composition in a mouse model 
of ALD compared to control mice. Specifically, the 
concentration of miR-122, miR-192, and miR-30a 
was found increased in EVs of alcohol-fed mice com-
pared to controls, presenting diagnostic capacity.(22) 
Notably, the levels of these miRs were also increased 
in serum EVs of patients with AH, indicating the 
Hepatology CommuniCations, Vol. 3, no. 2, 2019 Banales et al.
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potential value as disease biomarkers.(22) Although 
the mechanistic explanation for the increased levels 
of these miRs in EVs of ALD and AH needs to be 
revealed, it is important to note that miR-122 and 
miR-192 are highly abundant in hepatocytes and 
the increased levels of these miRs may be indicative 
of ongoing hepatocyte damage.(38-40) Furthermore, 
miR-30a regulates different steps of the autophagy 
process and MVB formation.(41) Thus, it is tempting 
to speculate that the miR-30a concentration in EVs 
may be the result of changes in autophagy and/or exo-
some production in ALD. Another study also found 
increased EV levels in a mouse model of AH.(42) This 
study identified mitochondrial DNA in the cargo of 
MVs that showed a biological effect in mediating 
neutrophil activation in AH.
Mass spectrometry analysis of serum EVs from a 
mouse model of ALD revealed specific changes in the 
EV protein cargo compared to controls.(43) Expression 
of proteins related to immune cell movement, pattern 
recognition receptors, interleukin-8 (IL-8) signal-
ing, endoplasmic reticulum stress, unfolded protein 
response, and hypoxia inducible factor signaling were 
different between ALD and control EVs. There were 
also specific proteins exclusively identified in ALD 
EVs and not in control EVs, indicating a potential 
disease-specific protein signature.(43) Of note, transfer 
of ALD EVs to naive healthy mice resulted in recruit-
ment of inflammatory monocytes and neutrophil leu-
kocytes in the recipient livers, with these immune cells 
showing a proinflammatory phenotype.(43) Heat shock 
protein 90, a major regulator of multiple cellular func-
tions, was identified as uniquely increased in ALD 
EVs and as a regulator of these biological effects.(43) 
These results indicate that circulating EVs have 
potential to modulate cell recruitment and function in 
distant organs. In a biodistribution study using miR-
155 as an indicator of biodistribution, intravenously 
Fig. 2. Extracellular vesicles in ALD. (A) EVs are released from different cell types in the liver and provide communication between 
hepatocytes and immune cells as well as within immune cells, through miRs. (B) miR signals that promote M1 (classically activated) or 
M2 (alternatively activated) macrophage polarization contribute to the mixed M1/M2 phenotype of macrophages in the liver in ALD. 
(C) Circulating EVs from chronic alcohol-fed mice induce liver inf lammation and macrophage polarization in alcohol-naive recipient 
mice. Abbreviations: HO, Heme oxygenase; Hsp, heat shock protein; TGFβ, transforming growth factor β.
Banales et al. Hepatology CommuniCations, February 2019
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administered EVs from wild-type mice rapidly (10 
minutes) reached many organs, including the liver.(44) 
In miR-155-deficient recipient mice, miR-155 trans-
ferred in EVs was found most abundantly in the liver 
and adipose tissue and to a lesser extent in lung, kid-
ney, and muscle tissue.(44) miR-155 transferred by 
EVs was taken up by specific cells in the liver, such 
as hepatocytes and macrophages, further regulating 
biological activities in these cells.(44) These results 
indicate a rapid biodistribution and cellular uptake of 
miRs in recipient mice and tissues in vivo.
The exposure of hepatocytes, liver macro-
phages, and Kupffer cells to alcohol was found to 
increase EV release in all cell types in vitro.(45,46) 
Functionally, these EVs produced by different liver 
cells act as messengers on target cells. This is sup-
ported by observations where hepatocyte-derived 
EVs that were enriched in miR-122 were taken 
up by monocytes that normally have no or very 
low levels of miR-122, modifying the phenotype 
of the recipient monocytes and resulting in lipo-
polysaccharide (LPS) sensitization and increased 
LPS-dependent proinflammatory cytokine produc-
tion compared to monocytes that received control 
EVs.(45) Furthermore, EVs derived from monocytes 
after alcohol exposure also had functional capacity 
to modulate naive monocyte function to result in 
an M2-like repair phenotype.(46) Alcohol exposure 
also increased miR-27a content in monocyte-de-
rived EVs, and their transfer to recipient naive 
monocytes induced an M2-like phenotype.(46) EVs 
can be loaded with specific miR inhibitors or pre-
cursors, being potential therapeutic vehicles for liver 
diseases.(45) Alcohol was also shown to stimulate 
macrophage activation through hepatocyte-derived 
release of CD40L-containing EVs in a caspase-de-
pendent manner.(25)
HCC
The correct numeration and phenotypic charac-
terization of EVs can be regarded as tracers for the 
presence of specific cells, i.e., immunocytes associ-
ated with NAFLD(7) or malignant tumor cells,(47) 
among others. Therefore, the tumor-associated (ta) 
EVs, also known as taMVs/taMPs, might help in 
the detection/diagnosis of cancer. Evidence suggests 
that EV shedding is not dependent on a metastatic 
cancer phenotype.(48) Therefore, the use of EVs as 
an advanced tool for a novel kind of liquid biopsy 
marker eventually revealing tumor presence, entity, 
location, and stage/diameter might be possible. 
However, a main challenge is the quest for specific 
antigens on EVs that could help in the identifica-
tion of specific EVs derived from the cancer cells 
(Fig. 3). A pioneering study identified glypican 
(GPC)-1 on the surface of pancreatic cancer-de-
rived EVs, which showed 100% sensitivity (SEN) 
and SPE for the diagnosis of early and late-stage 
pancreatic cancer compared to healthy subjects and 
to patients with a benign pancreatic disease.(49) 
However, GPC1+ EVs were also found elevated in 
patients with breast cancer, suggesting that this could 
be a potential pan-cancer biomarker. Moreover, 
patients with hepatitis C virus presented a differ-
ential immune cell-derived MV pattern (i.e., from 
lymphocytes [CD4+, CD8+] or natural killer T cells 
and macrophages/monocytes [CD14+]) compared to 
patients with NAFLD.(7) These data suggest that 
the simultaneous combination of cancer cell-derived 
antigens in MVs might be useful in the diagnosis 
of specific cancer entities. This approach resulted 
first in the use of a pan-cancer marker based on epi-
thelial cell adhesion molecule (EpCAM)+CD147+ 
MPs/MVs(48) that was further refined and validated 
for the diagnosis of hepatobiliary tumors, such as 
HCC and CCA.(47) In fact, it was confirmed that 
AnnexinV+EpCAM+CD147+ MVs/MPs were ele-
vated in HCC and CCA as in other investigated 
tumor entities and that asialoglycoprotein receptor 1 
(ASGPR1)+AnnexinV+EpCAM+CD133+ was more 
specific for hepatic disorders, such as nonmalignant 
cirrhosis (liver fibrosis F4 stage), HCC, and CCA. 
This was expected because ASGPR1 is a commonly 
used hepatocyte marker and therefore added hepa-
toma specificity to the antigen combination of the 
MVs. Patients with liver cancer (HCC or CCA), par-
ticularly early stage tumors, presented higher serum 
concentration of AnnexinV+EpCAM+ASGPR1+ 
taMPs compared to patients with nonmalignant 
hepatic cirrhosis (SEN, 75%; SPE, 47%),(47) indi-
cating the potential value of taMPs for the early 
diagnosis of liver cancer in patients with cirrhosis. 
However, a main question is whether taEVs bear 
the potential to be applied as a minimally invasive 
liquid biopsy marker. In this regard, proteomic anal-
ysis of serum EV from patients with HCC revealed 
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good potential candidates that must be investigated 
in future studies.(50)
Cholangiopathies
The presence of EVs in bile was described in 2010 
as a consequence of the secretory activities from both 
hepatocytes and cholangiocytes.(21) Contrary to the 
initial idea in which EVs were considered as a release 
mechanism of waste molecules, EVs in bile regulate 
the biology of cholangiocytes. Under physiological 
conditions, bile EVs are able to bind to the primary 
cilium of cholangiocytes, inhibiting their proliferation 
and promoting the characteristic quiescent status of 
the biliary epithelium.(21)
EVs are also important in cholangiopathies, regu-
lating different pathologic processes and containing 
potentially helpful biomarkers for the noninvasive 
diagnosis of these diseases. The value of bile and 
serum EVs as a source of biomarkers (e.g., miRs, 
lncRNAs, or proteins) for cholangiopathies has been 
investigated. Up-regulation of an miR panel (i.e., 191, 
486-3p, 1274b, 16, 484) was described in bile EVs 
from patients with CCA compared to control individ-
uals (i.e., patients with PSC, a known risk factor for 
CCA, biliary obstruction, or bile leak syndrome) with 
diagnostic significance (SEN, 67%; SPE, 96%).(51) In 
addition, two lncRNAs (ENST00000588480.1 and 
ENST00000517758.1) were reported up-regulated in 
bile EVs from patients with CCA compared to bil-
iary obstruction conditions (SEN, 83%; SPE, 59%; 
area under the receiver operating characteristic curve 
[AUROC], 0.709).(52)
Different protein profiles were found in serum 
EVs from patients with CCA, PSC, HCC, or healthy 
individuals (control group).(50) Patients with HCC 
presented higher EV concentrations compared to the 
other three groups in the study. Single protein anal-
ysis provided several proteins with diagnostic value 
and maximum AUROC values of 0.878 for amino-
peptidase N (AMPN; SEN, 91%; SPE, 66%) in CCA 
versus control and 0.905 for polymeric immunoglob-
ulin receptor (PIGR; SEN, 75%; SPE, 95%) in CCA 
stage I-II versus control. These two AUROC values 
are similar to the results obtained for the nonspecific 
Fig. 3. Potential cellular origins of EVs. Lymphocytes and nonmalignant cells eventually secrete exosomes and MVs, whereas 
malignant tumor cells can also secrete taMVs/taMPs and ta-EXOs). The center box represents the typical EV content usually found 
in the full blood of patients with cancer, including the few taMVs/taMPs/taEXOs (inferior numbers). Abbreviation: EXO, exosome.
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tumor marker carbohydrate antigen 19-9 (CA19.9), 
commonly used to help in the diagnosis of CCA 
(AUROC, 0.907 and 0.916, respectively). Notably, 
the combination of six biomarkers (AMPN, VNN1, 
PIGR, C-reactive protein, gamma-glutamyltransfer-
ase 1 [GGT1], and fibrogenin [FIBG]) resulted in 
an AUROC value of 0.991 (SEN, 98%; SPE, 97%) 
in CCA versus control. Likewise, AMPN provided 
a maximum area under the curve value of 0.789 for 
the diagnosis of PSC versus control (SEN, 83%; 
SPE, 63%), and its combination with six additional 
biomarkers (ficolin [FCN]-1, nuclear export protein, 
PIGR, VNN1, GPC5C, immunoglobulin kappa vari-
able 3-01) increased this value to 0.989 (SEN, 93%; 
SPE, 100%). A maximum AUROC value of 0.796 
for FIBG was reported for CCA versus PSC, and the 
combination of seven biomarkers (alpha-1-acid gly-
coprotein 1, S100A8, A10A9, small archaeal modifier 
proteins, GGT1, FCN2, immunoglobulin heavy con-
stant alpha 1) increased this value to 0.956 (SEN, 88%; 
SPE, 93%) compared to 0.819 of CA19.9. Moreover, 
the stratification of patients with CCA resulted in a 
maximum AUROC value of 0.956 for FCN2 in CCA 
stage I-II versus patients with PSC compared to the 
0.736 value of CA19.9. When comparing HCC ver-
sus control, galectin-3-binding protein provided a 
maximum AUROC value of 0.904 (SEN, 97%; SPE, 
72%) compared to 0.802 for alpha-fetoprotein (AFP; 
commonly used to help in the diagnosis of HCC). 
Furthermore, FIBG provided a maximum AUROC 
value of 0.894 (SEN, 83%; SPE, 90%) for the diag-
nosis of intrahepatic CCA versus HCC compared to 
CA19.9 (0.801) and AFP (0.753) values. Remarkably, 
although these biomarkers are present in EVs, they 
can be equally detected by immunoblot using total 
serum, which could be helpful for future validation 
studies and potential translation of the results into a 
clinical setting.(50)
EVs in serum can be secreted by multiples cells, 
including cancer cells. An orthotopic mouse model of 
human CCA showed the presence of specific human 
proteins in serum EVs of these mice, pointing out the 
role of tumor-derived EVs for biomarker discovery 
and as potential regulators of disease progression (i.e., 
metastasis, immune regulation).(50) Furthermore, total 
EV concentration could also help in the diagnosis of 
Fig. 4. Cholangiocarcinoma-derived EVs regulate tumor growth and the microenvironment and are a source of biomarkers in 
biological f luids. Abbreviations: CIK, cytokine-induced killer; TNF, tumor necrosis factor.
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malignant common bile duct stenosis (i.e., pancreatic 
cancer and CCA) compared to nonmalignant con-
ditions (i.e., chronic pancreatitis or biliary stones) as 
a higher concentration of EVs was reported in bile 
(AUROC, 1.000) and serum (AUROC, 0.813) of the 
malignant group.(53)
EVs may also regulate the pathogenesis of biliary 
diseases (Fig. 4). EVs secreted by human CCA cells 
contain oncogenic proteins (i.e., epidermal growth 
factor receptor, integrin-β4, agrin, disintegrin, and 
metalloproteinase domain-containing protein 10, 
among others) involved in the promotion of can-
cer cell proliferation, survival, and migration.(50,54,55) 
These cancer EVs are able to regulate the tumor 
microenvironment. CCA-derived EVs promote the 
differentiation of mesenchymal stem cells into fibro-
blasts and the secretion of IL-6, which ultimately 
stimulates CCA proliferation.(56) CCA-derived EVs 
are also able to inhibit the antitumor capacity of 
cytokine-induced killer cells by down-regulating the 
secretion of tumor necrosis factor alpha and perfo-
rin.(57) On the other hand, the serum concentration 
of the cholangiocyte-derived exosomal lncRNA H19 
increases under certain cholestatic conditions, further 
promoting hepatocellular injury and fibrosis.(58)
Conclusions and Future 
Directions
Increasing evidence points to the significant role 
of EVs in liver pathobiology, participating in inter-
cellular and interorgan communications, and emerg-
ing as a new opportunity for biomarker discovery and 
therapy. It is now evident that EVs participate in the 
development and progression of certain liver diseases, 
including NAFLD/NASH, ALD/AH, HCC, CCA, 
and other cholangiopathies, which are being postu-
lated as potential targets for therapy. However, EVs 
also participate in the pathogenesis of other types 
of liver diseases/conditions not discussed in the EV 
Symposium of the International Liver Conference 
2018 (e.g., drug-induced liver injury, viral hepatitis, 
and liver fibrosis, among others). Several inhibitors 
of EV biogenesis, release, and/or uptake are available, 
but their safety, efficacy, and selectivity need to be 
further evaluated at the preclinical and clinical level. 
The different concentration and/or composition of 
EVs in certain liver diseases provide a unique oppor-
tunity for biomarker discovery. Moreover, all studies 
involving EVs require their adequate experimental 
 characterization(59) as indicated by the International 
Society of Extracellular Vesicles. In sum, EVs repre-
sent a new and promising field of research in liver dis-
eases that deserves future investigation.
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